
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline Inc. demonstrated robust financial performance in fiscal year 2024, with Supply Chain Solutions generating $13 billion in revenue, reflecting a 12% year-over-year increase and accounting for 51% of total revenues. The company's adjusted EBITDA reached $3.4 billion, marking a 21% year-over-year growth and a corporate-wide EBITDA margin of 13.2%. Medline's consistent revenue growth during economic downturns, evidenced by a 17% CAGR during the 2008-2009 financial crisis and an 11% CAGR during COVID-19, underscores the resilience and demand stability of its medical-surgical products and supply chain solutions.
Bears say
The financial outlook for Medline Inc appears negative due to several fundamental reasons. Firstly, the healthcare sector is experiencing significant challenges, including low margins exacerbated by inflation, staffing shortages, and reduced patient volumes due to fewer insured individuals, which could lead to constrained revenue growth. Additionally, Medline's existing debt load may limit its capacity for mergers and acquisitions, hindering potential top-line growth opportunities, while increased competition for key customers poses further risks to revenue and earnings stability.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares